People allergic to peanuts may have a new way to protect themselves from severe allergic reactions to accidental peanut exposure. It's called sublingual immunotherapy—or SLIT—and it involves putting a miniscule amount of liquefied peanut protein under the tongue, where it is absorbed immediately into the blood stream to desensitize the immune system to larger amounts of peanut protein.
Published in the Journal of Allergy and Clinical Immunology, the research led by first author Edwin Kim, MD, assistant professor of medicine at the UNC School of Medicine, shows that SLIT could offer patients a safe and effective way to protect themselves from severe allergic reactions or even anaphylaxis.
"As a parent of two children with nut allergies, I know the fear parents face and the need for better treatments," said Kim, member of the UNC Children's Research Institute. "We now have the first long-term data showing that sublingual immunotherapy is safe and tolerable, while offering a strong amount of protection."
There are three main immunotherapeutic ways clinician scientists have developed to treat nut allergies, and all of them attempt to desensitize the immune system to nut proteins to help patients avoid severe allergic reactions. According to Kim, about 100 mg of peanut protein can trigger a severe allergic reaction. That's the sort of trace amount people fear can show up in food "manufactured in a facility that processes peanuts." For reference, one peanut kernel contains about 300 mg.
"The main idea beyond immunotherapy is not for kids to be able to eat peanut butter and jelly sandwiches," Kim said. "It's to keep them safe from the small hidden exposures that could occur with packaged foods, at restaurants, and with other food exposures."
One immunotherapy method involves a patch on the skin that releases a small amount of peanut protein through the skin to desensitize the immune system. This approach has proved safe in clinical research but perhaps not as effective as researchers had hoped. It could become an FDA-approved treatment.
A second approach is called oral immunotherapy (OIT), which is currently under FDA review and a decision is expected this year. OIT requires patients to ingest a small portion of peanut protein daily, and over the course of time this can desensitize the immune system to accidental exposures. In a large phase 3 OIT clinical trial, patients initially ingested 0.5 mg of peanut and increased the amount to 300 mg over the course of many weeks and then maintained that 300 mg daily intake for the remainder of the year. This trial showed substantial effectiveness in protecting patients but some patients suffered serious side effects. A subsequent meta-analysis of OIT clinical trial data published in The Lancet in April suggested that more clinical research on OIT was needed due to the risk of serious side effects.
A third approach is SLIT. Instead of having patients ingest peanut protein, doctors place a small amount of peanut protein under patients' tongues, where it is immediately absorbed. Because the peanut protein avoids digestion, patients are given much less peanut protein—about 0.0002 mg initially. This amount then increases over the course of months to just 2 mg.
In 2011, Kim and colleagues—including Wesley Burks, MD, dean of the UNC School of Medicine—conducted a small study of 18 patients to show that SLIT was safe and effective over the course of one year. Since then, Kim and colleagues followed 48 patients in the SLIT protocol of 2 mg daily for five years. In the JACI paper, the researchers showed that 67 percent of these patients were able to tolerate at least 750 mg of peanut protein without serious side effects. About 25 percent could tolerate 5000 mg.
Kim's data shows SLIT was about as effective as OIT, though the SLIT study was much smaller. And SLIT posed much less risk of serious side effects. The most common side effect was itchiness around the mouth that lasted about 15 minutes and did not need treatment. No one left the multi-year study because of side effects.
"SLIT participants tolerated between 10 and 20 times more peanut protein than it would take for someone to get sick," Kim said. "We think this provides a good cushion of protection—maybe not quite as good as OIT—but with an easier mechanism (sublingually) and, as far as we can tell right now, a better safety signal."
Kim's lab has finished a separate SLIT study of 4 mg daily for 55 patients over the course of four years. He hopes to publish results later this year. "With sublingual immunotherapy, we hope we can maintain our safety profile while seeing an even stronger benefit for patients," Kim said.
Kim and colleagues are also studying SLIT in a subset of children ages 1 to 4 because separate OIT data indicated these youngest patients have a stronger, more lasting benefit to immunotherapy.
"We focus on the idea there is no one perfect drug for food allergy," Kim said. "There will have to be a lot of shared decisions between physicians, patients, and parents about what method of treatment is best for each patient. We think SLIT could be a good option for a subset of patients."
More information: Lauren Herlihy et al. Five Year Follow-Up Of Early Intervention Peanut OIT Showed Characteristics of Sustained and Prolonged Clinical Benefit, Journal of Allergy and Clinical Immunology (2019). DOI: 10.1016/j.jaci.2018.12.806
AR101 Oral Immunotherapy for Peanut Allergy, New England Journal of Medicine (2018). DOI: 10.1056/NEJMoa1812856
Derek K Chu et al. Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety, The Lancet (2019). DOI: 10.1016/S0140-6736(19)30420-9
Provided by University of North Carolina Health Care